Lumipulse® G ADxPLORER® NPTX2
Immunoassay to be used with the automated LUMIPULSE® G1200 system for the quantitative measurement of neuronal pentraxin-2 (NPTX2) in human serum, plasma and cerebrospinal fluid (CSF).
This product is For Research Use Only (RUO), not for use in diagnostic procedures.
Product number 70101
Product number 70102
Product number 70103
Click here to navigate
- Contact sales for information
- Details
- Conditions of sale
- Insights
- Product inquiry
- Related products
- Webinars
-
Details
Synaptic dysfunction is an early-stage indicator of pathological progression and neurodegeneration and appears to correlate with the degree of cognitive decline1. NPTX2 could potentially be a relevant synaptic biomarker for monitoring disease progression or treatment response in patients with neurodegenerative diseases such as dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), Parkinson's disease (PD) and psychiatric disorders such as schizophrenia1,2, however its clinical utility remains to be further established. In addition, it may represent an important therapeutic target for TDP-43 proteinopathies3.
The Lumipulse® G ADxPLORER® NPTX2 assay was developed using a proprietary NPTX2 monoclonal antibody ADx410 (90582) in conjunction with an alkaline phosphatase-conjugated Fab fragment derived from recombinant mAb ADx409 (90578). The assay is calibrated with recombinant NPTX2 full length protein.
References:
- Das et al. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia. Alzheimers Res Ther. 2023 Mar 24;15(1):62.
- Göverti et al. Neuronal pentraxin-2 (NPTX2) serum levels during an acute psychotic episode in patients with schizophrenia. Psychopharmacology (Berl). 2022 Aug;239(8):2585-2591.
- Hruska-Plochan et al. A model of human neural networks reveals NPTX2 pathology in ALS and FTLD. Nature. 2024 Feb;626(8001):1073-1083.
Lumipulse is a registered trademark of Fujirebio Inc.
ADxPLORER is a registered trademark of Fujirebio Europe NV. -
Conditions of sale
Please contact fnce@fujirebio.com to obtain the end user conditions of sales for this product.
-
Insights
Mar 31, 2026Integration of ADx NeuroSciences within Fujirebio unleashes a world of new possibilities
Fujirebio Europe N.V. will formally and fully integrate ADx NeuroSciences N.V. into its organization on April 1, 2026. This completes a process that...
Jul 23, 2025Fujirebio introduces its Neuro Expert Toolbox (NExT) at AAIC 2025
Fujirebio is introducing its Neuro Expert Toolbox (NExT) for the first time at AAIC 2025 (Alzheimer's Association International Conference®) in...
Nov 13, 2024Video - Alzheimer's awareness redefined
Follow the journey of the Sullivan family and leading Alzheimer’s Neurologist and Researcher Dr. David Greeley as they introduce and explain these...
-
Product inquiry
-
Related products